S. 2295 (112th): Patient Safety and Generic Labeling Improvement Act
Apr 18, 2012
112th Congress, 2011–2013
Died in a previous Congress
This bill was introduced on April 18, 2012, in a previous session of Congress, but was not enacted.
Senior Senator from Vermont
Read Text »
Last Updated: Apr 18, 2012
Length: 2 pages
About the bill
- Full Title
A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.
Referred to Committee
Last Action: Apr 18, 2012
- What is a bill?
The “S.” in “S. 2295” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
7 cosponsors (7D) (show)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 19, 2012)
- Committee Assignments
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
- Find Similar Bills
Search for similar bills.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act. Retrieved from https://www.govtrack.us/congress/bills/112/s2295
“S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act.” www.GovTrack.us. 2012. February 27, 2015 <https://www.govtrack.us/congress/bills/112/s2295>
|title=S. 2295 (112th)
|accessdate=February 27, 2015
|author=112th Congress (2012)
|date=April 18, 2012
|quote=Patient Safety and Generic Labeling Improvement Act